irinotecan has been researched along with Lassitude in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (42.86) | 29.6817 |
| 2010's | 20 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Han, D; Li, S; Ren, X; Shang, W; Sun, L; Wang, G; Xu, L | 1 |
| Fan, Z; Liu, B; Lu, T; Tong, H | 1 |
| Aleba, A; Bachet, JB; Barbier, E; Breysacher, G; Brocard, F; Desauw, C; Di Fiore, F; Dupuis, OJM; Etienne, PL; Lagasse, JP; Lecomte, T; Lepage, C; Levache, CB; Lucidarme, O; Pernot, S; Raoul, JL; Taieb, J | 1 |
| Ahmed, S; Chalchal, H; Haider, K; Moser, M; Olson, C; Papneja, N; Shaw, J; Tan, K; Zaidi, A | 1 |
| Banerjee, A; Boyett, JM; Fangusaro, J; Fouladi, M; Friedman, HS; Gajjar, A; Gilbertson, RJ; Goldman, S; Gururangan, S; Jakacki, R; Kun, LE; McLendon, RE; Onar-Thomas, A; Packer, RJ; Pollack, IF; Poussaint, TY; Warren, KE; Wu, S | 1 |
| Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA | 1 |
| Brutcher, E; Chen, Z; El-Rayes, BF; Hawk, N; Kauh, J; Kim, S; Kooby, DA; Landry, J; Mahaseth, H; Maithel, SK | 1 |
| Beau, J; Innominato, PF; Iurisci, I; Karaboue, A; Lévi, F; Madrid, JA; Moreau, T; Ortiz-Tudela, E; Rol, MA | 1 |
| Cao, Y; Gong, J; Li, J; Li, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Wu, Y; Zhang, X; Zhou, J | 1 |
| Allendorf, DJ; Bordoni, RE; Dixon, PM; Grant, SC; Jerome, ML; Miley, DK; Reddy, VB; Robert, F; Saleh, MN; Singh, KP | 1 |
| Bayever, E; Belanger, B; Blanc, JF; Bodoky, G; Braiteh, F; Chen, LT; Chiu, CF; Cunningham, D; Dean, A; Dhindsa, N; Hubner, RA; Jameson, G; Lee, KH; Li, CP; Macarulla, T; Moyo, V; Schwartsmann, G; Shan, YS; Siveke, JT; Von Hoff, DD; Wang-Gillam, A | 1 |
| Jensen, HA; Krogh, M; Pfeiffer, P; Qvortrup, C; Sorbye, H; Vestermark, LW; Winther, SB; Zubcevic, K | 1 |
| Lee, JR; Oh, PJ | 1 |
| Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J | 1 |
| Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E | 1 |
| Bozkurt, MT; Cirak, Y; Degirmenci, M; Demir Piskin, G; Durusoy, R; Gorumlu, G; Karabulut, B; Karaca, B; Sanli, UA; Tunali, D; Uslu, R | 1 |
| Dehais, C; Delattre, JY; Golmard, JL; Jouniaux-Delbez, N; Liou, A; Nguyen, BK; Souvannavong, V; Tadrist, C | 1 |
| Bufill, J; Burns, M; Cardenes, H; Chiorean, EG; Clark, R; Coleman, N; Curie, C; Hinkle, DT; LeBlanc, J; Loehrer, PJ; Robb, B; Sanghani, S; Schiel, MA; Tong, Y; Yu, M | 1 |
| Gao, F; Linehan, D; Lockhart, AC; Lubner, S; McWilliams, R; Menias, C; Peddi, PF; Picus, J; Sorscher, SM; Suresh, R; Tan, BR; Wang, J; Wang-Gillam, A | 1 |
| Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M | 1 |
| Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA | 1 |
| Adams, AL; Brady, D; Engstrom, PF; Gallo, JM; Kilpatrick, D; Lewis, NL; Litwin, S; Meropol, NJ; Scher, R; Szarka, CE; Weiner, LM | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Kaufmann, SH; Miller, LL; Pitot, HC; Rubin, J; Sloan, JA | 1 |
| Hirano, T; Kubo, H; Masaki, K; Ogura, H; Taoka, H; Terauchi, F; Yamamoto, Y | 1 |
| Arai, T; Goto, A; Hamaguchi, T; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y; Yasui, H | 1 |
| Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J | 1 |
| Bearden, JD; Blackstock, AW; Butler, J; Case, LD; Ennever, PR; Ho, C; Howerton, R; Levine, E; Magrinat, GC; Melin, S; Minotto, DC; Mishra, G | 1 |
| Chung, KY; Flombaum, C; Saltz, L; Schrag, D | 1 |
| Bisonni, R; Leon, A; Lippe, P; Lombardo, M; Marcucci, F; Massacesi, C; Mattioli, R; Pilone, A; Rocchi, MB; Terrazzino, S | 1 |
| Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J | 1 |
| Amado, RG; Berlin, J; Hecht, JR; Malik, I; Meropol, NJ; Navale, L; Patnaik, A; Tchekmedyian, S; Venook, A | 1 |
| Kelsen, DP; Kemeny, NE; O'Reilly, EM; Raeburn, L; Saltz, LB; Sanz-Altamira, PM; Schwartz, GK; Steger, CM; Stuart, KE | 1 |
| Algazy, K; Giantonio, B; Haller, DG; Hardy, C; Kluijtmans, LA; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Whitehead, AS | 1 |
| Ajani, JA; Baker, J; Charnsangavej, C; Feig, BW; Ho, L; Mansfield, PF; Pisters, PW | 1 |
4 review(s) available for irinotecan and Lassitude
| Article | Year |
|---|---|
Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Topics: Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Diarrhea; Etoposide; Fatigue; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Nausea; Neoplasm Staging; Neutropenia; Odds Ratio; Proportional Hazards Models; Small Cell Lung Carcinoma; Thrombocytopenia; Vomiting | 2017 |
The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Fluorouracil; Humans; Irinotecan; Leucovorin; Nausea; Neutropenia; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2018 |
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypertension; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; Rectal Neoplasms; Retrospective Studies; Vascular Endothelial Growth Factor A | 2010 |
Cetuximab therapy and symptomatic hypomagnesemia.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Fatigue; Humans; Hypocalcemia; Incidence; Irinotecan; Magnesium; Magnesium Deficiency; Male; Severity of Illness Index | 2005 |
25 trial(s) available for irinotecan and Lassitude
| Article | Year |
|---|---|
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fatigue; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Oxaliplatin; Paresthesia; Progression-Free Survival; Rectal Neoplasms; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Fatigue; Hemorrhage; Humans; Hypertension; Infant; Injections, Intravenous; Irinotecan; Neoplasm Recurrence, Local; Proteinuria; Young Adult | 2013 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2014 |
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Brain Diseases, Metabolic; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Endonucleases; Etoposide; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitosis; Multiple Organ Failure; Pneumonia; Treatment Outcome; Weight Loss | 2015 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2016 |
Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Combinations; Fatigue; Female; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neutropenia; Prospective Studies; Survival Analysis; Treatment Outcome | 2009 |
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Thymidine Phosphorylase; Treatment Outcome | 2012 |
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2012 |
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Quality of Life; Time Factors; Treatment Outcome; Venous Thrombosis | 2013 |
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2013 |
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Quinazolines; Thiophenes | 2002 |
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Neutropenia | 2002 |
Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Fatigue; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Shock, Septic; Stomatitis; Survival Rate | 2004 |
Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Thrombocytopenia; Vomiting | 2005 |
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon-Nitrogen Ligases; Carcinoma; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Predictive Value of Tests; Promoter Regions, Genetic; Quinazolines; Thiophenes; Thymidylate Synthase; Vomiting | 2006 |
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Treatment Outcome | 2006 |
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Skin Diseases; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Diarrhea; Fatigue; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Prognosis; Treatment Outcome; Vomiting | 2001 |
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Fatigue; Female; Genotype; Homocysteine; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasms; Neutropenia; Oxidoreductases Acting on CH-NH Group Donors; Quinazolines; Thiophenes | 2001 |
CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Fatigue; Female; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Stomach Neoplasms; Treatment Outcome | 2002 |
6 other study(ies) available for irinotecan and Lassitude
| Article | Year |
|---|---|
Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Community Health Planning; Deoxycytidine; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Saskatchewan | 2019 |
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Female; Filgrastim; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Treatment Outcome | 2013 |
The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circadian Rhythm; Fatigue; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Monitoring, Physiologic; Motor Activity; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Rest; Weight Loss | 2014 |
[Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Esophagogastric Junction; Fatigue; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Pyrimidines; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab | 2014 |
[Effect of Cancer Symptoms and Fatigue on Chemotherapy-related Cognitive Impairment and Depression in People with Gastrointestinal Cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Anxiety; Camptothecin; Cognitive Dysfunction; Depression; Drug Therapy, Combination; Fatigue; Female; Fluorouracil; Gastrointestinal Neoplasms; Hemoglobins; Humans; Irinotecan; Male; Memory; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Surveys and Questionnaires; Translating | 2016 |
[An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Diagnostic Self Evaluation; Fatigue; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Recurrence; Surveys and Questionnaires | 2011 |